NRX Pharmaceuticals (NRXP) Restructuring Costs (2023 - 2026)

NRX Pharmaceuticals (NRXP) has reported Restructuring Costs for 4 consecutive years, with $4000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Restructuring Costs changed N/A year-over-year to $4000.0 in Q2 2026; TTM through Jun 2026 was -$66000.0, a 94.01% increase from a year earlier, with the FY2025 full-year figure at $36000.0, up 103.0% from the prior year.
• Restructuring Costs was $4000.0 for Q2 2026 at NRX Pharmaceuticals, up from -$6000.0 in the prior quarter.
• Over five years, Restructuring Costs peaked at $250000.0 in Q2 2023 and troughed at -$1.2 million in Q4 2024.
• A 4-year average of -$102250.0 and a median of $17000.0 in 2025 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs surged 102.5% in 2025 and sank 106.0% in 2026, its largest moves.
• Over 4 years, Restructuring Costs stood at $250000.0 in 2023, then slumped by 580.8% to -$1.2 million in 2024, then surged by 102.5% to $30000.0 in 2025, then slumped by 86.67% to $4000.0 in 2026.
• The last three Restructuring Costs figures came in at $4000.0 (Q2 2026), -$6000.0 (Q1 2026), and $30000.0 (Q4 2025), per Business Quant data.